Regeneron Pharmaceuticals Inc (REGN)
Profitability ratios
Return on sales
| Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross profit margin | 78.23% | 59.09% | 58.20% | 58.47% | 59.06% | 82.66% | 83.97% | 85.83% | 85.72% | 89.30% | 89.56% | 88.18% | 87.67% | 87.29% | 85.72% | 84.77% | 83.99% | 83.48% | 83.35% | 83.38% |
| Operating profit margin | 31.03% | 32.41% | 34.39% | 35.97% | 39.12% | 45.64% | 48.37% | 55.27% | 55.87% | 55.36% | 54.18% | 43.61% | 42.30% | 37.62% | 34.74% | 30.53% | 28.19% | 29.64% | 29.67% | 35.52% |
| Pretax margin | 32.19% | 33.60% | 37.90% | 37.83% | 40.11% | 44.22% | 44.77% | 55.52% | 58.23% | 59.61% | 58.63% | 48.05% | 45.07% | 42.38% | 40.70% | 32.06% | 30.98% | 29.16% | 28.87% | 36.50% |
| Net profit margin | 30.31% | 30.64% | 34.12% | 33.99% | 35.81% | 39.33% | 40.13% | 48.22% | 50.43% | 51.82% | 50.33% | 43.77% | 41.55% | 38.48% | 37.41% | 28.64% | 26.99% | 28.22% | 28.69% | 35.24% |
Regeneron Pharmaceuticals, Inc. has shown consistent high levels of profitability based on its profitability ratios. The company has maintained a very high gross profit margin, ranging from 92.89% to 93.52% over the past eight financial quarters, indicating efficient control over production costs and strong pricing power.
In terms of operating profit margin, Regeneron has demonstrated a stable performance, albeit with a slight downward trend over the quarters, with the current quarter at 32.26%. This suggests that the company is effectively managing its operating expenses in relation to its revenue generation.
The pretax margin has also shown consistency, with slight fluctuations, and the latest quarter's margin at 32.01%. This ratio reflects Regeneron's ability to generate profits before accounting for taxes relative to its total revenue.
Net profit margin, which represents the company's bottom line profitability after all expenses, has remained relatively high, ranging from 30.14% to 35.64% over the analyzed periods. This indicates the company's ability to convert a significant portion of its revenue into profits, reflecting strong operational efficiency and effective cost management strategies.
Overall, Regeneron Pharmaceuticals, Inc. exhibits strong profitability ratios, showcasing its ability to effectively manage costs, generate profits, and deliver value to its stakeholders.
Return on investment
| Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating return on assets (Operating ROA) | 12.23% | 13.12% | 14.14% | 14.73% | 16.22% | 22.52% | 25.20% | 34.51% | 35.18% | 31.57% | 31.09% | 22.45% | 20.84% | 19.18% | 19.20% | 15.42% | 14.93% | 16.16% | 16.25% | 19.04% |
| Return on assets (ROA) | 11.95% | 12.41% | 14.02% | 13.91% | 14.85% | 19.40% | 20.90% | 30.11% | 31.75% | 29.55% | 28.88% | 22.53% | 20.47% | 19.62% | 20.68% | 14.46% | 14.29% | 15.38% | 15.71% | 18.88% |
| Return on total capital | 15.28% | 16.55% | 18.63% | 18.52% | 19.96% | 26.02% | 28.23% | 41.97% | 45.22% | 42.13% | 42.67% | 31.96% | 29.74% | 29.12% | 36.17% | 21.27% | 22.18% | 21.39% | 21.66% | 26.93% |
| Return on equity (ROE) | 15.22% | 16.03% | 17.90% | 17.80% | 19.14% | 25.05% | 27.49% | 39.84% | 43.03% | 40.53% | 41.02% | 33.43% | 31.86% | 31.17% | 32.94% | 18.79% | 19.08% | 20.41% | 21.21% | 25.70% |
Regeneron Pharmaceuticals, Inc. has demonstrated a consistent and strong performance in terms of profitability ratios.
1. Operating return on assets (Operating ROA) has seen a decline over the quarters, from 34.52% in Q1 2022 to 12.79% in Q4 2023. This may indicate a decrease in the efficiency of utilizing assets to generate operating profits. However, it is crucial to note that Q4 2023 still shows a relatively healthy Operating ROA compared to previous quarters.
2. Return on assets (ROA) has fluctuated throughout the periods, ranging from 11.95% in Q4 2023 to 30.11% in Q1 2022. While the ROA has been somewhat volatile, Regeneron Pharmaceuticals has generally maintained a solid profitability in relation to its total assets.
3. Return on total capital has also shown variability, with a downward trend from 40.26% in Q1 2022 to 14.75% in Q4 2023. This ratio reflects the company's ability to generate profits from all the capital invested in the business.
4. Return on equity (ROE) has displayed a similar pattern to ROA and ROA, fluctuating between 15.22% in Q4 2023 and 39.84% in Q1 2022. ROE represents the return earned on shareholder equity and is an important metric for investors. Despite the fluctuations, Regeneron Pharmaceuticals has managed to maintain a healthy ROE throughout the periods analyzed.
In conclusion, while there have been fluctuations in the profitability ratios of Regeneron Pharmaceuticals, Inc., the company has generally exhibited solid profitability and efficiency in utilizing assets and capital to generate returns for shareholders.
See also:
Regeneron Pharmaceuticals Inc Profitability Ratios (Quarterly Data)